Fortress Biotech, Inc.
NASDAQRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Fortress Biotech, Inc. (NASDAQ:FBIOP) is a biopharmaceutical company that acquires, develops, and commercializes innovative pharmaceutical and biotechnology products targeting oncology, dermatology, rare diseases, and other therapeutic areas; it operates through segments including Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development. The company markets dermatology products through partner Journey Medical Corporation, such as Emrosi (minocycline hydrochloride extended-release capsules) for rosacea; Qbrexza (medicated cloth towelette) for primary axillary hyperhidrosis; Accutane (oral isotretinoin) for severe recalcitrant nodular acne; Amzeeq and Zilxi for acne; Targadox, Ximino, and Exelderm; as well as additional offerings like Ceracade and Luxamend. Its development-stage pipeline features late-stage candidates including intravenous tramadol for post-operative acute pain; CUTX-101 (copper histidinate injection) for Menkes disease with recent NDA acceptance; UNLOXCYT (cosibelimab) for metastatic cutaneous squamous cell carcinoma; olafertinib for EGFR mutation-positive NSCLC; CAEL-101 (monoclonal antibody) for amyloid light chain amyloidosis; Triplex (cytomegalovirus vaccine); and dotinurad for gout advancing in Phase 3 trials; early-stage assets encompass MB-101, MB-108, and MB-109 for glioblastoma; MB-106 for B-cell non-Hodgkin lymphoma; AJ201 (androgen receptor degradation enhancer); BAER-101; and preclinical programs like AAV-ATP7A gene therapy, AVTS-001, CK-103 (BET inhibitor), and others. Fortress Biotech maintains partnerships with leading institutions and companies including AstraZeneca, City of Hope, Nationwide Children’s Hospital, Columbia University, Dana-Farber Cancer Center, and Sentynl Therapeutics to advance its portfolio. Founded in 2006 and headquartered in Bay Harbor Islands, Florida, the company—formerly Coronado Biosciences, Inc., renamed in April 2015—recently completed the acquisition of subsidiary Checkpoint Therapeutics by Sun Pharma for approximately $28 million upfront plus potential contingent value right payments and royalties on UNLOXCYT sales; announced subsidiary Urica Therapeutics' involvement in Crystalys Therapeutics' $205 million Series A financing in October 2025 to accelerate global Phase 3 trials of dotinurad; launched Emrosi for rosacea treatment; reported third-quarter 2025 net revenue growth of 20.5% to $17.6 million; and entered a strategic AI collaboration with Partex in early 2025 to enhance asset identification and evaluation. Fortress Biotech focuses on U.S. and global markets through its subsidiaries and partners, leveraging its expertise to maximize value from commercial and clinical-stage assets.
Company News
Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Fortress Biotech: Is It Time To Pay The Deferred Preferred Stock Dividends?
Fortress Biotech to Participate in A.G.P.'s Annual Virtual Healthcare Conference
Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights
Fortress Biotech (NASDAQ:FBIOP) Stock Price Up 22.9% – Here’s What Happened
UPDATE: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States
Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
Fortress Biotech, Inc. (FBIO) Q3 2025 Earnings Call Transcript
Fortress Biotech (NASDAQ:FBIOP) Stock Price Down 1.9% – Time to Sell?
Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics' Global Phase 3 Trials of Dotinurad for the Treatment of Gout
Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $205 Million Series A Financing
Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101
Fortress Biotech to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics